

Resource Summary Report

Generated by SPARC SAWG on Aug 22, 2026

CD8a-VioGreen

RRID:AB_2659495

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-109-330, RRID:AB_2659495

Antibody Information

URL: http://antibodyregistry.org/AB_2659495

Proper Citation: Miltenyi Biotec Cat# 130-109-330, RRID:AB_2659495

Target Antigen: CD8a

Clonality: monoclonal

Comments: Discontinued: 7-2019; Target Distribution dendritic cells, NK cells, red blood cells, T cells, thymocytes; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:9 µg in 300 µL

Antibody Name: CD8a-VioGreen

Description: This monoclonal targets CD8a

Target Organism: mouse

Clone ID: REA601

Antibody ID: AB_2659495

Vendor: Miltenyi Biotec

Catalog Number: 130-109-330

Record Creation Time: 20250820T071804+0000

Record Last Update: 20250821T020221+0000

Ratings and Alerts

No rating or validation information has been found for CD8a-VioGreen.

Warning: Discontinued: 2021

Discontinued: 7-2019; Target Distribution dendritic cells, NK cells, red blood cells, T cells, thymocytes; target type CD markers, REAfinity Antibodies; tested applications MACS Flow Cytometry; quantity:9 µg in 300 µL

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Chaurasiya S, et al. (2021) Toward comprehensive imaging of oncolytic viroimmunotherapy. Molecular therapy oncolytics, 23, 303.

Kim SI, et al. (2021) Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity. Molecular cancer therapeutics, 20(1), 173.